Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 3, 2009, Pages 560-563

  Jaruratanasirikul, Sutep ^a   Sudsai, Teeratad ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

lactams; Carbapenems; Pharmacokinetic pharmacodynamic

Indexed keywords

CILASTATIN PLUS IMIPENEM; IMIPENEM;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; IMIPENEM; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLASMA; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 60649106757     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn543     Document Type: Article

References (19)

1. Nicolau D, Quintiliani R, Nightingale CH. Once-daily aminoglycosides. Conn Med 1992; 56: 561-3.
2. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.
3. Vogelman B, Gudmundsson S, Leggett J et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-47.
4. Craig WA, Ebert SC. Continuous infusion of β-lactam antibiotics. Antimicrob Agents Chemother 1992; 36: 2577-83.
5. Lipman J, Gomersall CD, Gin T et al. Continuous infusion ceftazidime in intensive care: A randomized controlled trial. J Antimicrob Chemother 1999; 43: 309-11.
6. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994; 38: 931-6.
7. Rodloff AC, Goldstein EJ, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother 2006; 58: 916-29.
8. Viaene E, Chanteux H, Servais H et al. Comparative stability studies of antipseudomonal β-lactam for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor operated syringes (intensive care units). Antimicrob Agents Chemother 2002; 46: 2327-32.
9. Jaruratanasirikul S, Raungsri N, Punyo J et al. Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion. J Antimicrob Chemother 2005; 56: 1163-5.
10. Jaruratanasirikul S, Sriwiriyajan S. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection. J Antimicrob Chemother 2003; 52: 518-21.
11. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-h infusion or bolus injection. Antimicrob Agents Chemother 2005; 49: 1337-9.
12. Ikawa K, Morikawa N, Ikeda K et al. Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: Use of population pharmacokinetic modeling and Monte Carlo simulation. Diagn Microbiol Infect Dis 2008; 62: 292-7.
13. Norrby SR, Faulkner KL, Newell PA. Differentiating meropenem and imipenem/cilastatin. Infect Dis Clin Pract 1997; 6: 291-303.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
15. Garcia-Capdevila L, Lopez-Calull C, Arroyo C et al. Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients. J Chromatogr B 1997; 692 127-32.
16. Drusano GL. Prevention of resistance: A goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36 Suppl 1: S42-50.
17. Tam VH, McKinnon PS, Akins RL et al. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002; 50: 425-8.
18. Belzberg H, Zhu J, Cornwell EE III et al. Imipenem levels are not predictable in the critically ill patient. J Trauma 2004; 56 111-7.
19. Giannoni E, Moreillon P, Cotting J et al. Prospective determination of plasma imipenem concentrations in critically ill children. Antimicrob Agents Chemother 2006; 50: 2563-8.